Novavax, Inc.

What they do

Novavax develops vaccines using its recombinant protein-based nanoparticle technology and its proprietary Matrix-M adjuvant, which is designed to boost and lengthen immune response and allow lower antigen doses. The platform is used in its own COVID-19 Vaccine (Nuvaxovid) and in the R21/Matrix-M adjuvant malaria vaccine developed by the Jenner Institute, University of Oxford, and manufactured by Serum Institute of India. The company also supplies Matrix-M to partners under material transfer agreements, including a preclinical oncology collaboration, and is advancing internal pipeline candidates such as a C. difficile vaccine.

Revenue drivers

• Sanofi collaboration — Revenue recognized under the license agreement including upfront payments, milestones, royalties and transition services reimbursement; this was $36M of $57M total Q2 2026 revenue and $199M of $239M in Q2 2025.
• Product sales (Supply Sales and Nuvaxovid Sales) — Supply Sales of finished product, adjuvant and other supplies to license partners were $19M in Q2 2026, up 47% year over year, driven by higher Matrix-M adjuvant demand; Nuvaxovid direct sales were $0 in Q2 2026.
• Licensing, royalties and other — Royalties from partners such as Sanofi (high teens to low twenties percent of Sanofi global net sales) plus milestone payments; this line generated $38M in Q2 2026 versus $229M in Q2 2025, which had included a $175M BLA-approval milestone and a $27M Takeda amendment.

Recent performance

Second quarter 2026 total revenue was $57 million, down 76% from $239 million in Q2 2025, which had included the $175 million U.S. BLA-approval milestone and $27 million Takeda amendment. Product sales rose 76% year over year to $19 million on higher Matrix-M adjuvant demand and partner supply sales. R&D expenses were $71 million, with $23 million reimbursed by partners, leaving $48 million net. Full-year 2025 revenue was $1.12 billion with net income of $440.3 million, but recent quarters have been much smaller: $147.1 million in Q4 2025 and $56.7 million in Q2 2026. The latest balance sheet (June 30, 2026) shows total assets of $955.6 million, total liabilities of $1.15 billion and negative shareholder equity of $190.7 million, with $191.5 million of cash.

Strategy

Novavax says its strategy is to maximize its Matrix-M adjuvant and R&D assets through partnerships while keeping a lean operating model. Under the Sanofi collaboration, Sanofi is expanding commercial reach of Nuvaxovid with launches in the UK, Germany and Canada from 2026 and is conducting a Phase 3 COVID-19-Influenza Combination trial that would trigger a $125 million milestone if initiated in the U.S. or EU. Completion of the manufacturing technology transfer to Sanofi is expected in mid-2027 and would trigger a $75 million milestone. The company is funding internal programs including a C. difficile vaccine, which has entered pre-IND interactions with the FDA and GMP manufacturing, with potential clinical entry as early as 2027.

Risks

• History of losses and financing need — The 10-K states Novavax has a history of losses and will require significant funding to maintain operations and develop candidates; it had negative shareholder equity of $190.7 million at June 30, 2026.
• Dependence on Sanofi and partner milestones — The 10-K warns that existing collaboration, funding and supply agreements, including the Sanofi CLA and advance purchase agreements, do not assure success, and failure to meet performance obligations could eliminate milestones, terminate agreements or require refunds.
• Reliance on third parties — The 10-K states Novavax relies on third parties for manufacturing its vaccine candidates and expects to continue doing so, increasing the risk of insufficient quantities or unacceptable costs.
• Regulatory and clinical uncertainty — Forward-looking statements flag the need to obtain and maintain FDA licensure or foreign approvals for the COVID-19 Vaccine, and risks that clinical and preclinical development is lengthy, expensive and uncertain.

Outlook

Management raised its full-year 2026 Revenue Framework and improved GAAP combined R&D and SG&A expense guidance by $10 million at the midpoint. It expects Sanofi to be among the first movers in the combination vaccine segment and cites a $125 million milestone for Phase 3 CIC trial initiation in the U.S. or EU and a $75 million milestone for completing the manufacturing technology transfer in mid-2027. The company says it is on track to advance its C. difficile vaccine into the clinic as early as 2027 and that multiple partner-led Matrix-M experiments are underway in infectious disease and oncology.